RxDoctor Payments Data

Bella Mehta, MD

Internal Medicine · New York, NYNPI 1801130034

Payments from drug & device makers

$26,134in general payments, 2019–2025

Across 64 payments — averaging $408.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$9K
  • Johnson & Johnson$6K
  • Tonix Medicines, Inc.$6K
  • Amgen$3K
  • Sanofi$496
  • Aurinia Pharma U.S., Inc.$412
  • plus $1K from 7 others

What the payments were for

  • Consulting fees$14,54256%
  • Speaking & faculty fees$5,93623%
  • Travel & lodging$1,3635%
  • Food & beverage$4,21616%
  • Education$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,134 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$25,296
Medicare patients
60
Services billed
1,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KevzaraSarilumab12$51,280
Hydroxychloroquine Sulfate91$2,833
MethotrexateMethotrexate Sodium61$1,445
Leflunomide11$881
Colchicine18$819
Celecoxib27$775
Folic Acid26$280
Alendronate Sodium30$206
Allopurinol14$167
Gabapentin16$165
Meloxicam34$157
Prednisone23$131
Leucovorin Calcium11$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiKevzara$496$51,28012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →